Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study
- PMID: 18024482
- PMCID: PMC2128658
- DOI: 10.1136/bmj.39376.447211.BE
Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study
Abstract
Objective: To determine whether financial ties to one drug company are associated with favourable results or conclusions in meta-analyses on antihypertensive drugs.
Design: Retrospective cohort study.
Setting: Meta-analyses published up to December 2004 that were not duplicates and evaluated the effects of antihypertensive drugs compared with any comparator on clinical end points in adults. Financial ties were categorised as one drug company compared with all others.
Main outcome measures: The main outcomes were the results and conclusions of meta-analyses, with both outcomes separately categorised as being favourable or not favourable towards the study drug. We also collected data on characteristics of meta-analyses that the literature suggested might be associated with favourable results or conclusions.
Results: 124 meta-analyses were included in the study, 49 (40%) of which had financial ties to one drug company. On univariate logistic regression analyses, meta-analyses of better methodological quality were more likely to have favourable results (odds ratio 1.16, 95% confidence interval 1.07 to 1.27). Although financial ties to one drug company were not associated with favourable results, such ties constituted the only characteristic significantly associated with favourable conclusions (4.09, 1.30 to 12.83). When controlling for other characteristics of meta-analyses in multiple logistic regression analyses, meta-analyses that had financial ties to one drug company remained more likely to report favourable conclusions (5.11, 1.54 to 16.92).
Conclusion: Meta-analyses on antihypertensive drugs and with financial ties to one drug company are not associated with favourable results but are associated with favourable conclusions.
Conflict of interest statement
Competing interests: None declared.
Figures
Comment in
-
Influence of pharmaceutical funding on the conclusions of meta-analyses.BMJ. 2007 Dec 8;335(7631):1167. doi: 10.1136/bmj.39381.655845.BE. Epub 2007 Nov 16. BMJ. 2007. PMID: 18024481 Free PMC article.
-
Financial ties that might bind: Consider palliative coronary intervention.BMJ. 2008 Jan 12;336(7635):59. doi: 10.1136/bmj.39450.691169.3A. BMJ. 2008. PMID: 18187701 Free PMC article. No abstract available.
-
Financial ties that might bind: Delve deeper to find the links.BMJ. 2008 Jan 12;336(7635):59. doi: 10.1136/bmj.39450.701262.3A. BMJ. 2008. PMID: 18187702 Free PMC article. No abstract available.
References
-
- Krimsky S, Rothenberg L, Stott P, Kyle G. Financial interests of authors in scientific journals: a pilot study of 14 publications. Sci Eng Ethics 1996;2:395-410. - PubMed
-
- Blumenthal D, Campbell E, Causino N, Louis K. Participation of life-science faculty in research relationships with industry. N Engl J Med 1996;335:1734-9. - PubMed
-
- Campbell E, Louis K, Blumenthal D. Looking a gift horse in the mouth: corporate gifts supporting life sciences research. JAMA 1998;279:995-9. - PubMed
-
- Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65. - PubMed
-
- Boyd E, Bero L. Assessing faculty financial relationships with industry: a case study. JAMA 2000;284:2209-14. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical